Skip to main content

Table 2 Eosinophil surface proteins reported to respond to intervention

From: Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases

Protein Observation Reference
αL integrin (CD11a) Decreased by anti-IL-5 (mepolizumab) after segmental lung antigen challenge (in mild allergic asthma) [1]
αM integrin (CD11b) Decreased by anti-IL-5 (mepolizumab) after segmental lung antigen challenge (in mild allergic asthma) [1]
β2 integrin (CD18) Decreased by anti-IL-5 (mepolizumab) after segmental lung antigen challenge (in mild allergic asthma) [1]
Decreased by topical corticosteroids (in EoE) [6]
CCR3 (CD193) Decreased by anti-IL-5 (mepolizumab) (in EoE) [11]
IL-2Rα (CD25) Decreased by corticosteroid and other anti-inflammatory drug treatment [7]
IL-5Rα (CD125) Increased by anti-IL-5 (mepolizumab) [1]
PSGL-1 (CD162) Decreased by anti-IL-5 (mepolizumab) after segmental lung antigen challenge (in mild allergic asthma) [1]
Activated β2 integrin (CD18) Intermediate state (recognized by mAb KIM-127) decreased by anti-IL-5 (mepolizumab) (in mild allergic asthma) [1]
  1. Note: Observations refer to expression level, usually determined by flow cytometry, and are on blood eosinophils